Last reviewed · How we verify
Role of ALiskiren, a Direct Renin Inhibitor, in Preventing Atrial Fibrillation in Patients With a Pacemaker; RALF. A Double-blind, Randomized, Parallel-group, Single Centre Study
The aim of the study is to find out whether aliskiren reduces atrial fibrillation burden measured with a pacemaker device
Details
| Lead sponsor | Mika Lehto |
|---|---|
| Phase | Phase 3 |
| Status | UNKNOWN |
| Enrolment | 70 |
| Start date | 2012-01 |
| Completion | 2017-12 |
Conditions
- Atrial Fibrillation
Interventions
- aliskiren
Primary outcomes
- burden of atrial fibrillation — From the start of the study to the end of the study; 0 - 12 months
Countries
Finland